GLP-1 RAs linked to lower risk among those with type 2 diabetes and without diabetes; greater protection seen versus metformin, insulin. (HealthDay News) — Glucagon-like peptide 1 receptor agonists ...

For both GLP-1 RA users and controls, there was an increase in the incidence of NSHL, telogen effluvium (TE), androgenetic alopecia (AGA), and alopecia areata between 2014 and 2024.

A systematic review and meta-analysis published in Hepatology has revealed that GLP-1 receptor agonists and SGLT2 inhibitors are associated with lower risks of liver-related events and hepatocellular ...

Combined GLP 1 receptor agonists and progestin therapy reduces endometrial cancer risk and hysterectomy rates in women with benign uterine conditions.

Research has suggested that GLP-1 receptor agonists may have protective effects against certain eye conditions, but they have also been linked to rare ophthalmic complications. In this retrospective ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.